[ANIP] ANI Pharmaceuticals, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 622.64 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 63.26 Change: 0.76 (1.22%)
Ext. hours: Change: 0 (0%)

chart ANIP

Refresh chart

Description: ANI Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals. The company manufactures oral solid dose products, as well as liquids and topicals, narcotics, and potent products; and Lithobid lithium carbonate extended release tablets. Its targeted areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company offers generic products, including Esterified Estrogen with Methyltestosterone tablets for use in treating vasomotor symptoms of menopause; Fluvoxamine Maleate to treat obsessions and compulsions in patients with obsessive-compulsive disorder; Hydrocortisone Enema for the treatment of ulcerative colitis; Metoclopramide syrup for treating heartburn symptoms with gastroesophageal reflux disease; and Opium Tincture to treat severe diarrhea by slowing the movement of the intestines, as well as branded p

Fundamental Ratios
Shares Outstanding11.49 M EPS0.7 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 182.82% Sales Growth - Q/Q-10.64% P/E64.69
P/E To EPS Growth P/S9.75 P/BV4.3 Price/Cash Per Share
Price/Free Cash Flow29.77 ROA11.19% ROE20.56% ROI
Current Ratio22.37 Quick Ratio21.19 Long Term Debt/Equity Debt Ratio0.06
Gross Margin81.84% Operating Margin40.83% Net Profit Margin46.59% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities20 K Cash From Investing Activities-4.61 M Cash From Operating Activities1.12 M Gross Profit16.05 M
Net Profit4.37 M Operating Profit9.57 M Total Assets265.99 M Total Current Assets202.99 M
Total Current Liabilities9.07 M Total Debt112.17 M Total Liabilities121.25 M Total Revenue18.8 M
Technical Data
High 52 week74.56 Low 52 week41.17 Last close60.78 Last change0.7%
RSI73.85 Average true range1.73 Beta0.82 Volume99.67 K
Simple moving average 20 days6.06% Simple moving average 50 days15.18% Simple moving average 200 days1.77%
Performance Data
Performance Week-0.2% Performance Month14.27% Performance Quart4.85% Performance Half-11.04%
Performance Year26.07% Performance Year-to-date35.01% Volatility daily1.61% Volatility weekly3.6%
Volatility monthly7.37% Volatility yearly25.53% Relative Volume340.74% Average Volume72.78 K
New High New Low


2020-06-01 08:30:00 | ANI Pharmaceuticals Provides Update on Recent Regulatory Filing

2020-05-09 08:21:23 | Earnings Release: Here's Why Analysts Cut Their ANI Pharmaceuticals, Inc. NASDAQ:ANIP Price Target To US$45.67

2020-05-08 18:30:40 | ANI Pharmaceuticals Inc ANIP Q1 2020 Earnings Call Transcript

2020-05-08 07:12:52 | Edited Transcript of ANIP earnings conference call or presentation 7-May-20 2:30pm GMT

2020-05-07 09:55:01 | ANI Pharmaceuticals ANIP Q1 Earnings and Revenues Surpass Estimates

2020-05-07 08:30:00 | ANI Pharmaceuticals Reports First Quarter 2020 Results and Appoints Interim CEO

2020-05-01 11:50:03 | Are Investors Undervaluing ANI Pharmaceuticals ANIP Right Now?

2020-04-30 08:30:00 | ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2020 Financial Results

2020-04-29 08:30:00 | ANI Receives Refusal to File Letter from FDA for Cortrophin® Gel

2020-04-24 06:45:54 | The ANI Pharmaceuticals NASDAQ:ANIP Share Price Is Down 40% So Some Shareholders Are Getting Worried

2020-04-14 08:30:00 | ANI Announces Upcoming Departure of CEO

2020-04-13 08:30:00 | ANI Announces FDA Acceptance of Supplemental Filing for Cortrophin® Gel 80 U/mL

2020-04-02 08:30:00 | ANI Pharmaceuticals Announces Launch of Omega-3-Acid Ethyl Esters Capsules USP

2020-03-26 08:30:00 | ANI Announces Launch of Polyethylene Glycol 3350, 17g/Packet

2020-03-24 08:30:00 | ANI Pharmaceuticals Announces the Filing of a Prior Approval Supplement for Purified Cortrophin® Gel 80 U/mL

2020-03-10 06:40:18 | A Sliding Share Price Has Us Looking At ANI Pharmaceuticals, Inc.'s NASDAQ:ANIP P/E Ratio

2020-03-05 07:17:12 | New Strong Sell Stocks for March 5th

2020-03-04 15:27:50 | Edited Transcript of ANIP earnings conference call or presentation 27-Feb-20 3:30pm GMT

2020-03-02 08:30:00 | ANI Pharmaceuticals Announces FDA Approval of Memantine Hydrochloride Extended-Release Capsules

2020-02-29 07:35:28 | Earnings Miss: ANI Pharmaceuticals, Inc. Missed EPS By 53% And Analysts Are Revising Their Forecasts

2020-02-27 10:05:03 | ANI Pharmaceuticals ANIP Q4 Earnings and Revenues Lag Estimates

2020-02-27 08:30:00 | ANI Pharmaceuticals Reports Full Year and Fourth Quarter 2019 Results, Provides 2020 Guidance and Remains on Track to Submit Cortrophin® Gel sNDA to FDA in March 2020

2020-02-24 12:45:35 | 3 Fast-Growing CapEx Stocks

2020-02-21 05:25:39 | Read This Before Judging ANI Pharmaceuticals, Inc.'s NASDAQ:ANIP ROE

2020-02-20 08:30:00 | ANI Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter and Year-to-Date 2019 Financial Results

2020-02-19 12:31:05 | Earnings Preview: ANI Pharmaceuticals ANIP Q4 Earnings Expected to Decline

2020-02-12 08:30:00 | ANI Announces Launch of Sulfamethoxazole and Trimethoprim Oral Suspension USP 200 mg/40 mg per 5 mL

2020-01-24 08:30:00 | ANI Announces Launch of Tolterodine Extended-Release Capsules

2020-01-16 08:30:00 | ANI Pharmaceuticals Announces FDA Approval of Potassium Citrate Extended-Release Tablets USP

2020-01-16 05:39:03 | Is ANI Pharmaceuticals, Inc.'s NASDAQ:ANIP CEO Pay Justified?

2020-01-14 08:30:00 | ANI Announces Launch of Paliperidone Extended-Release Tablets

2020-01-09 08:30:00 | ANI Pharmaceuticals Announces Acquisition of Commercial and Pipeline Generic Products from Amerigen Pharmaceuticals, Ltd.

2019-12-19 10:09:23 | 4 Drug/Biotech Outperformers That May Lose Steam in 2020

2019-12-18 08:30:00 | ANI Pharmaceuticals Announces Launch of Bretylium Tosylate Injection, USP 50 mg/mL

2019-12-11 13:55:23 | Is ANI Pharmaceuticals Inc ANIP Going To Burn These Hedge Funds ?

2019-12-11 05:06:28 | Before You Buy ANI Pharmaceuticals, Inc. NASDAQ:ANIP, Consider Its Volatility

2019-12-04 09:21:02 | New Strong Sell Stocks for December 4th

2019-12-04 07:45:12 | Moving Average Crossover Alert: ANI Pharmaceuticals

2019-11-26 08:30:00 | ANI Pharmaceuticals to Present at Evercore ISI 2nd Annual HealthCONx Conference

2019-11-22 17:19:22 | Edited Transcript of ANIP earnings conference call or presentation 6-Nov-19 3:30pm GMT

2019-11-11 06:25:39 | Estimating The Intrinsic Value Of ANI Pharmaceuticals, Inc. NASDAQ:ANIP

2019-11-06 09:55:02 | ANI Pharmaceuticals ANIP Lags Q3 Earnings and Revenue Estimates

2019-11-06 08:30:00 | ANI Pharmaceuticals Reports Third Quarter Results

2019-11-06 08:21:28 | The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings

2019-10-31 08:30:00 | ANI Announces Plans to Launch Bretylium Tosylate Injection, USP 500mg/10ml 50mg/ml for Ventricular Arrhythmias

2019-10-30 08:30:00 | ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2019 Financial Results

2019-10-29 10:33:02 | ANI Pharmaceuticals ANIP to Report Q3 Results: Wall Street Expects Earnings Growth

2019-10-29 08:30:00 | ANI Pharmaceuticals announces the launch of ANI Global Source, its contract development and manufacturing business

2019-10-28 16:14:16 | Here is What Hedge Funds Think About ANI Pharmaceuticals Inc ANIP

2019-10-12 08:26:30 | Does ANI Pharmaceuticals NASDAQ:ANIP Deserve A Spot On Your Watchlist?